U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C20H22N4O2
Molecular Weight 350.4143
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of C-1311

SMILES

CCN(CC)CCNC1=CC=C2N=CN3C2=C1C(=O)C4=C3C=CC(O)=C4

InChI

InChIKey=CUNDRHORZHFPLY-UHFFFAOYSA-N
InChI=1S/C20H22N4O2/c1-3-23(4-2)10-9-21-15-6-7-16-19-18(15)20(26)14-11-13(25)5-8-17(14)24(19)12-22-16/h5-8,11-12,21,25H,3-4,9-10H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C20H22N4O2
Molecular Weight 350.4143
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

C-1311 is an imidazoacridinone analog. It is a next-generation investigational anticancer drug. It is an antitumor inhibitor of topoisomerase II and FMS-like tyrosine kinase 3 receptor. It was evaluated in phase I and II clinical trials for the treatment of various types of tumors. Mild treatment-related adverse events were thrombocytopenia, anemia, nausea, vomiting and diarrhea. Serious adverse event is neutropenia.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P06786
Gene ID: 855636.0
Gene Symbol: TOP2
Target Organism: Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)
8.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18828924 DOI: 10.1200/jco.2008.26.15_suppl.1055
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
640 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 640 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 640 mg/m2, 1 times / week
Sources:
unhealthy
Health Status: unhealthy
Sex: unknown
Food Status: UNKNOWN
Sources:
DLT: neutropaenia...
Dose limiting toxicities:
neutropaenia (grade 4, 2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
neutropaenia grade 4, 2 patients
DLT
640 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 640 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 640 mg/m2, 1 times / week
Sources:
unhealthy
Health Status: unhealthy
Sex: unknown
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

In Vivo Use Guide
Sources: DOI: 10.1200/jco.2008.26.15_suppl.1055
The initial dose was 480 mg/m2, 1 hr IV infusion on d 1, 8, and 15 of a 28 day cycle.
Route of Administration: Intravenous
In Vitro Use Guide
Acute treatments (3 h) of the a human tumour line (HeLa S3) revealed that cells exposed to C-1311 levels, which first induced persistent G2 arrest (0.5 ug/ml), subsequently died from this compartment, while doses exceeding these levels (1.0 ug/ml), paradoxically, did not cause the same extensive cell death.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:57:22 GMT 2025
Edited
by admin
on Mon Mar 31 18:57:22 GMT 2025
Record UNII
MZ4Y5H4OAB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
C-1311
Common Name English
NSC-645809
Preferred Name English
XLS-002
Common Name English
SYMADEX
Common Name English
C 1311
Common Name English
IMIDAZOACRIDONE
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID10160508
Created by admin on Mon Mar 31 18:57:22 GMT 2025 , Edited by admin on Mon Mar 31 18:57:22 GMT 2025
PRIMARY
ChEMBL
CHEMBL338604
Created by admin on Mon Mar 31 18:57:22 GMT 2025 , Edited by admin on Mon Mar 31 18:57:22 GMT 2025
PRIMARY
NSC
645809
Created by admin on Mon Mar 31 18:57:22 GMT 2025 , Edited by admin on Mon Mar 31 18:57:22 GMT 2025
PRIMARY
MESH
C098965
Created by admin on Mon Mar 31 18:57:22 GMT 2025 , Edited by admin on Mon Mar 31 18:57:22 GMT 2025
PRIMARY
FDA UNII
MZ4Y5H4OAB
Created by admin on Mon Mar 31 18:57:22 GMT 2025 , Edited by admin on Mon Mar 31 18:57:22 GMT 2025
PRIMARY
PUBCHEM
132127
Created by admin on Mon Mar 31 18:57:22 GMT 2025 , Edited by admin on Mon Mar 31 18:57:22 GMT 2025
PRIMARY
CAS
138154-39-9
Created by admin on Mon Mar 31 18:57:22 GMT 2025 , Edited by admin on Mon Mar 31 18:57:22 GMT 2025
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
time- and concentration-dependent inhibitor
Related Record Type Details
ACTIVE MOIETY